0001209191-24-001770.txt : 20240117
0001209191-24-001770.hdr.sgml : 20240117
20240117170332
ACCESSION NUMBER: 0001209191-24-001770
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240112
FILED AS OF DATE: 20240117
DATE AS OF CHANGE: 20240117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Readnour Robin Shane
CENTRAL INDEX KEY: 0001914883
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41331
FILM NUMBER: 24539201
MAIL ADDRESS:
STREET 1: 3835 CLEGHORN AVENUE, SUITE 300
CITY: NASHVILLE
STATE: TN
ZIP: 37215
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AN2 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001880438
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 820606654
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1800 EL CAMINO REAL, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94027
BUSINESS PHONE: (650) 331-9090
MAIL ADDRESS:
STREET 1: 1800 EL CAMINO REAL, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94027
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-12
0
0001880438
AN2 Therapeutics, Inc.
ANTX
0001914883
Readnour Robin Shane
C/O AN2 THERAPEUTICS, INC.
1800 EL CAMINO REAL, SUITE D
MENLO PARK
CA
94027
1
0
0
0
1
Common Stock
2024-01-12
4
S
0
706
21.92
D
414788
I
See footnotes
Common Stock
2024-01-12
4
S
0
719
21.91
D
485073
I
See footnotes
The reported sale of 706 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on August 30, 2023.
This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.96. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
Shares held directly by MGC 2018 LP.
The reported sale of 719 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023.
This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
Shares held directly by MGC 2018 QP.
/s/ Jay Ferguson, Attorney-in-Fact for Robin Shane Readnour
2024-01-17